Literature DB >> 10543762

Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

S O Matsumura1, L Louie, M Louie, A E Simor.   

Abstract

Using checkerboard and time-kill assays, we evaluated the in vitro activity of quinupristin-dalfopristin (RP 59500) alone and in combination with five other antimicrobial agents against 12 clinical strains of vancomycin-resistant Enterococcus faecium (VREF). In time-kill studies, six VREF strains exhibited synergism with the combination of quinupristin-dalfopristin and doxycycline and three exhibited synergism with quinupristin-dalfopristin plus ampicillin-sulbactam. Combinations of quinupristin-dalfopristin with these and other agents warrant further clinical evaluation for the treatment of serious VREF infections.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10543762      PMCID： PMC89558     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.

Authors:  S Dutka-Malen; S Evers; P Courvalin
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

2.  Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.

Authors:  S Matsumura; A E Simor
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

3.  In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.

Authors:  C R Messick; S L Pendland
Journal:  Diagn Microbiol Infect Dis       Date:  1997-11       Impact factor: 2.803

4.  In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

Authors:  R C Mercier; S R Penzak; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Species identification of enterococci via intergenic ribosomal PCR.

Authors:  G J Tyrrell; R N Bethune; B Willey; D E Low
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

6.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool.

Authors:  A G Miranda; K V Singh; B E Murray
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

8.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Authors:  W Brumfitt; J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

9.  Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

Authors:  R N Jones; H S Sader; M E Erwin; S C Anderson
Journal:  Diagn Microbiol Infect Dis       Date:  1995-02       Impact factor: 2.803
View more
  7 in total

Review 1.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Authors:  Christopher D Doern
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

3.  Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.

Authors:  I Raad; R Hachem; H Hanna; E Girgawy; K Rolston; E Whimbey; R Husni; G Bodey
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.

Authors:  G M Eliopoulos; C B Wennersten
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen.

Authors:  Christy A Beneri; David P Nicolau; Howard S Seiden; Lorry G Rubin
Journal:  Infect Drug Resist       Date:  2008-08-12       Impact factor: 4.003

7.  Synergistic Action of AMX Associated with 1,8-Cineole and Its Effect on the ESBL Enzymatic Resistance Mechanism.

Authors:  Ahmed Amin Akhmouch; Soukayna Hriouech; Aouatef Mzabi; Mariam Tanghort; Hanane Chefchaou; Adnane Remmal; Najat Chami
Journal:  Antibiotics (Basel)       Date:  2022-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.